Acylated GLP-1 compounds

Details for Australian Patent Application No. 2006224536 (hide)

Owner Novo Nordisk A/S

Inventors Madsen, Kjeld; Lau, Jesper; Dorwald, Florencio Zaragoza; Stephensen, Henrik; Bloch, Paw; Hansen, Thomas Kruse

Agent Shelston IP

Pub. Number AU-B-2006224536

PCT Pub. Number WO2006/097537

Priority 05102171.5 18.03.05 EP

Filing date 20 March 2006

Wipo publication date 21 September 2006

Acceptance publication date 5 April 2012

International Classifications

C07K 14/605 (2006.01) Peptides having more than 20 amino acids

A61K 38/26 (2006.01) Medicinal preparations containing peptides - Glucagons

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

19 July 2007 PCT application entered the National Phase

  PCT publication WO2006/097537 Priority application(s): WO2006/097537

5 April 2012 Application Accepted

  Published as AU-B-2006224536

2 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006224537-Extended GLP-1 compounds

2006224533-1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication